[vc_row][vc_column][vc_column_text css=”.vc_custom_1653578362527{margin-bottom: 0px !important;}”]In the past, we published a list of drug patents expiring in 2023 and 2024. The list saw tremendous interest from people in the generic pharmaceutical industry. And why not?
With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible. We totally get it. And keeping that very thought in mind, we collated a list of 65 drugs that are going off-patent in 2025. We also included other information like dosage information, ingredients, and the diseases they cure. This could help you easily choose the most profitable drug to develop a generic version of.
Loved the idea and the list? Thank us later in the comments section. Now onto the list.
The article has a list of drug patents expiring in 2025. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][mk_fancy_title color=”#2878bf” size=”32″ line_height=”80″ font_weight=”bolder” txt_transform=”uppercase” margin_bottom=”0″ font_family=”none”]Drug Patents Expiring in 2025[/mk_fancy_title][mk_divider margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Xalkori
Crizotinib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$524 Million (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8785632 | March 01, 2025 |
| US7230098 | August 26, 2025 |
| US7858643 | October 8, 2029 |
| US8217057 | November 6, 2029 |
[/mk_table][vc_column_text css=”.vc_custom_1614617336773{margin-bottom: 0px !important;}”]Dosage: Capsule; Oral
Company: Pfizer
Ingredients: Crizotinib
Treatment: Non-Small Cell Lung Carcinoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Omegaven
Fish Oil Triglycerides[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9566260 | July 11, 2025 |
| US9629821 | July 11, 2025 |
| US10350186 | November 05, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1614617426560{margin-bottom: 0px !important;}”]Dosage: Emulsion; Intravenous
Company: Fresenius Kabi USA LLC
Ingredients: Fish Oil Triglycerides
Treatment: Parenteral Nutrition-Associated Cholestasis (PNAC)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Yupelri
Revefenacin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$3.3 Million (Q4, 2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7491736 | March 10, 2025 |
| US7521041 | March 10, 2025 |
| US7550595 | March 10, 2025 |
| US7585879 | March 10, 2025 |
| US7910608 | March 10, 2025 |
| US7288657 | December 23, 2025 |
| US10550081 | July 14, 2030 |
| US9765028 | July 14, 2030 |
| US8541451 | August 25, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1614617497838{margin-bottom: 0px !important;}”]Dosage: Solution; Inhalation
Company: Mylan Ireland Ltd
Ingredients: Revefenacin
Treatment: Chronic Obstructive Pulmonary Disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sprycel
Dasatinib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$2 Billion (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8680103 | February 04, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1614617588284{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: Bristol Myers Squibb Co
Ingredients: Dasatinib
Treatment: Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Bosulif
Bosutinib Monohydrate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$477 Million (2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7417148 | December 11, 2025 |
| US7767678 | November 23, 2026 |
| US7919625 | December 11, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1614617649837{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: PF Prism CV
Ingredients: Bosutinib Monohydrate
Treatment: Chronic Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Cresemba
Isavuconazonium Sulfate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$180 Million (Jul 2018 – Jun 2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6812238 | October 31, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1614617728712{margin-bottom: 0px !important;}”]Dosage: Capsule; Oral
Company: Astellas Pharma US Inc
Ingredients: Isavuconazonium Sulfate
Treatment: Invasive Aspergillosis And Mucormycosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Antara
Fenofibrate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$70 Million (2008)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8026281 | April 22, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1614617787095{margin-bottom: 0px !important;}”]Dosage: Capsule; Oral
Company: Lupin Inc
Ingredients: Fenofibrate
Treatment: High Cholesterol and Triglycerides (fatty acids) in Blood[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][vc_accordion_tab title=”Section”][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Lysteda
Tranexamic Acid[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$25 Million (2012)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7947739 | March 04, 2025 |
| US8022106 | March 04, 2025 |
| US8273795 | March 04, 2025 |
| US8487005 | March 04, 2025 |
| US8791160 | March 04, 2025 |
| US8809394 | March 04, 2025 |
| US8957113 | March 04, 2025 |
| US9060939 | March 04, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1614617884856{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: Amring Pharmaceuticals Inc
Ingredients: Tranexamic Acid
Treatment: Cyclic Heavy Menstrual Bleeding[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Bepreve
Bepotastine Besilate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$160.3 Million (2011)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8784789 | January 13, 2025 |
| US8877168 | July 30, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614617975867{margin-bottom: 0px !important;}”]Dosage: Solution/Drops; Ophthalmic
Company: Bausch And Lomb Inc
Ingredients: Bepotastine Besilate
Treatment: Itching of the Eyes due to Allergies[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sancuso
Granisetron[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$20 – $25 Million[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7608282 | January 22, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1614618045033{margin-bottom: 0px !important;}”]Dosage: Film, Extended Release; Transdermal
Company: Kyowa Kirin Inc
Ingredients: Granisetron
Treatment: Nausea and Vomiting Caused by Cancer Chemotherapy[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Nucynta
Tapentadol Hydrochloride[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$46.8 Million (2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7994364 | June 27, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1614618124017{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: Collegium Pharmaceuticals Inc
Ingredients: Tapentadol Hydrochloride
Treatment: Moderate to Severe Pain[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Nexlizet
Bempedoic Acid, Ezetimibe[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7335799 | December 03, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1614618203951{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: Esperion Therapeutics Inc
Ingredients: Bempedoic Acid, Ezetimibe
Treatment: Reduce the Amount of Cholesterol and other Fatty Substances in Blood[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Vyzulta
Latanoprostene Bunod[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8058467 | January 5, 2025 |
| US7910767 | January 5, 2025 |
| US7273946 | October 3, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653030873591{margin-bottom: 0px !important;}”]Dosage: Eye Drops
Company: Bausch & Lomb
Ingredients: LATANOPROSTENE BUNOD
Treatment: Intraocular Pressure in Patients with Open-angle Glaucoma or Ocular Hypertension[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Trilipix
Fenofibrate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7259186 | January 7, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653030974453{margin-bottom: 0px !important;}”]Dosage: Oral
Company: AbbVie Inc
Ingredients: CHOLINE FENOFIBRATE
Treatment: Abnormal Blood Lipid Levels[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Duaklir
Aclidinium bromide/formoterol[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE46417 | February 10, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653031049850{margin-bottom: 0px !important;}”]Dosage: Inhalation
Company: ALMIRALL, S.A
Ingredients: ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE
Treatment: Chronic Obstructive Pulmonary Disease (COPD)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Arcapta
Indacaterol[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6878721 | February 25, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653031125593{margin-bottom: 0px !important;}”]Dosage: Inhalation
Company: Novartis
Ingredients: INDACATEROL MALEATE
Treatment: Chronic Obstructive Pulmonary Disease (COPD)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Rukobia
Fostemsavir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8461333 | February 25, 2025 |
| US7745625 | November 19, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1653031211949{margin-bottom: 0px !important;}”]Dosage: Oral
Company: ViiV Healthcare
Ingredients: FOSTEMSAVIR TROMETHAMINE
Treatment: HIV/AIDS[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Incivek
Telaprevir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7820671 | February 25, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653031271675{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Johnson & Johnson
Ingredients: TELAPREVIR
Treatment: Hepatitis C[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Viberzi
Eluxadoline[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US10213415 | March 14, 2025 |
| US8609709 | March 14, 2025 |
| US7786158 | March 14, 2025 |
| US9115091 | July 7, 2028 |
| US8691860 | July 7, 2028 |
| US7741356 | May 27, 2029 |
[/mk_table][vc_column_text css=”.vc_custom_1653031443309{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Allergan
Ingredients: ELUXADOLINE
Treatment: Diarrhea and Abdominal Pain[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Glucophage
Metformin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7780987 | March 23, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653031548443{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Merck & Co
Ingredients: METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Roxicodone
Oxycodone[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US10696684 | March 30, 2025 |
| US10407434 | March 30, 2025 |
| US9522919 | March 30, 2025 |
| US9073933 | March 30, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653031688710{margin-bottom: 0px !important;}”]Dosage: Oral, Sublingual, Intramuscular, Intravenous, Intranasal, Subcutaneous, Transdermal, Rectal, Epidural
Company: Xanodyne Pharmaceuticals
Ingredients: OXYCODONE HYDROCHLORIDE
Treatment: Moderate to Severe Pain[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Tegsedi
Inotersen[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8101743 | April 1, 2025 |
| US9061044 | April 29, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1653288517099{margin-bottom: 0px !important;}”]Dosage: Subcutaneous injection
Company: Akcea Therapeutics, Inc.
Ingredients: INOTERSEN SODIUM
Treatment: Nerve Damage in adults with Hereditary transthyretin-mediated Amyloidosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Reyvow
Lasmiditan[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7423050 | April 6, 2025 |
| US11053214 | December 5, 2037 |
[/mk_table][vc_column_text css=”.vc_custom_1653031799495{margin-bottom: 0px !important;}”]Dosage: Oral, Intravenous
Company: Eli Lilly and Company
Ingredients: LASMIDITAN SUCCINATE
Treatment: Migraine with or without Aura[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Kyprolis
Carfilzomib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.06 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8207125 | April 14, 2025 |
| US7232818 | April 14, 2025 |
| US8207297 | April 14, 2025 |
| US7417042 | July 20, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653031942443{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Amgen Inc.
Ingredients: CARFILZOMIB
Treatment: Relapsed or Refractory Multiple Myeloma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Biktarvy
Bictegravir/emtricitabine/tenofovir alafenamide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7390791 | April 17, 2025 |
| US9296769 | August 15, 2032 |
| US8754065 | August 15, 2032 |
| US9216996 | December 19, 2033 |
| US9732092 | December 19, 2033 |
| US9708342 | June 19, 2035 |
[/mk_table][vc_column_text css=”.vc_custom_1653032137907{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Gilead Sciences
Ingredients: BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Treatment: HIV/AIDS[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Stendra
Avanafil[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6656935 | April 27, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653032240883{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Vivus Inc.
Ingredients: AVANAFIL
Treatment: Erectile Dysfunction[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Inlyta
Axitinib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$93 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6534524 | April 29, 2025 |
| US8791140 | December 14, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653032333406{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Pfizer
Ingredients: AXITINIB
Treatment: Renal Cell Carcinoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Camptosar
Irinotecan[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9782349 | May 2, 2025 |
| US9724303 | May 2, 2025 |
| US8992970 | May 2, 2025 |
| US10722508 | May 2, 2025 |
| US8329213 | January 6, 2027 |
| US8147867 | August 29, 2028 |
[/mk_table][vc_column_text css=”.vc_custom_1653032876717{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Pfizer
Ingredients: IRINOTECAN HYDROCHLORIDE
Treatment: Colon Cancer and Small Cell Lung Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Jentadueto
Linagliptin/metformin hydrochloride[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7407955 | May 2, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653032974916{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Treatment: High Blood Sugar Levels caused by Type 2 Diabetes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Pexeva
Paroxetine mesylate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7598271 | May 4, 2025 |
| US8946251 | August 4, 2026 |
| US8658663 | April 6, 2029 |
[/mk_table][vc_column_text css=”.vc_custom_1653033098653{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Sebela Pharmaceutical
Ingredients: PAROXETINE MESYLATE
Treatment: Symptoms of Menopause[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Doptelet
Avatrombopag[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7638536 | May 5, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653033185682{margin-bottom: 0px !important;}”]Dosage: Oral
Company: AkaRx, Inc.
Ingredients: AVATROMBOPAG MALEATE
Treatment: Thrombocytopenia Associated with Chronic Liver Disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Lymphoseek
Technetium Tc 99m tilmanocept [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6409990 | May 12, 2025 |
| US9439985 | September 27, 2033 |
[/mk_table][vc_column_text css=”.vc_custom_1653033289059{margin-bottom: 0px !important;}”]Dosage: Subcutaneous injection
Company: Navidea Biopharmaceuticals
Ingredients: TECHNETIUM TC-99M TILMANOCEPT
Treatment: Identify Sentinel Lymph Nodes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Olysio
Simeprevir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7671032 | May 19, 2025 |
| US8349869 | July 28, 2026 |
| US8754106 | July 28, 2026 |
| US8741926 | July 28, 2026 |
| US9040562 | July 28, 2026 |
| US9856265 | July 28, 2026 |
| US8148399 | September 5, 2029 |
[/mk_table][vc_column_text css=”.vc_custom_1653033421452{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Johnson & Johnson
Ingredients: SIMEPREVIR SODIUM
Treatment: Hepatitis C[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Edarbi
Azilsartan[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7157584 | May 22, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653033504935{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Takeda Pharmaceutical
Ingredients: AZILSARTAN KAMEDOXOMIL
Treatment: Hypertension[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Onpattro
Patisiran[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8334373 | May 27, 2025 |
| US8168775 | October 20, 2029 |
| US10240152 | October 20, 2029 |
| US11079379 | August 27, 2035 |
[/mk_table][vc_column_text css=”.vc_custom_1653033633413{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Alnylam Pharmaceuticals
Ingredients: PATISIRAN SODIUM
Treatment: Polyneuropathy in People with Hereditary transthyretin-mediated Amyloidosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Diprivan
Propofol[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8476010 | June 1, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653033727037{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Fresenius Kabi
Ingredients: PROPOFOL
Treatment: Used to help Patients Relax before and during General Anesthesia for Surgery[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Kazano
Alogliptin/metformin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8288539 | June 24, 2025 |
| US7807689 | June 27, 2028 |
[/mk_table][vc_column_text css=”.vc_custom_1653033821462{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Takeda Pharmaceuticals
Ingredients: ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE
Treatment: Blood Sugar Control in Adults with Type 2 Diabetes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Amondys 45
Casimersen[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9447415 | June 28, 2025 |
| US8524880 | April 2, 2026 |
| US10287586 | November 12, 2030 |
| US9228187 | November 12, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653033930826{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Sarepta Therapeutics, Inc.
Ingredients: CASIMERSEN
Treatment: Duchenne Muscular Dystrophy (DMD)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Exondys 51
Eteplirsen[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US10781451 | June 28, 2025 |
| US9018368 | June 28, 2025 |
| US9243245 | October 27, 2028 |
[/mk_table][vc_column_text css=”.vc_custom_1653283088879{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Sarepta Therapeutics, Inc.
Ingredients: ETEPLIRSEN
Treatment: Duchenne Muscular Dystrophy (DMD)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Vyondys 53
Golodirsen[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US10227590 | June 28, 2025 |
| US9994851 | June 28, 2025 |
| US9024007 | June 28, 2025 |
| US10968450 | June 28, 2025 |
| US10421966 | June 28, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653283190536{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Sarepta Therapeutics, Inc.
Ingredients: GOLODIRSEN
Treatment: Duchenne Muscular Dystrophy (DMD)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Vyleesi
Bremelanotide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6794489 | June 28, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653283289981{margin-bottom: 0px !important;}”]Dosage: Subcutaneous
Company: Palatin Technologies
Ingredients: BREMELANOTIDE ACETATE
Treatment: Low Sexual Desire in Women[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Zydelig
Idelalisib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE44638 | August 5, 2025 |
| US8865730 | March 5, 2033 |
| US10730879 | March 5, 2033 |
| US9469643 | September 2, 2033 |
[/mk_table][vc_column_text css=”.vc_custom_1653283442208{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Gilead Sciences
Ingredients: IDELALISIB
Treatment: Blood Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Duzallo
Lesinurad/Allopurinol[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8003681 | August 25, 2025 |
| US8546436 | February 29, 2032 |
[/mk_table][vc_column_text css=”.vc_custom_1653283551624{margin-bottom: 0px !important;}”]Dosage: Oral
Company: AstraZeneca
Ingredients: ALLOPURINOL; LESINURAD
Treatment: Gout[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Prolensa
Bromfenac[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8129431 | September 11, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653283652461{margin-bottom: 0px !important;}”]Dosage: Eye Drops
Company: Bausch & Lomb
Ingredients: BROMFENAC SODIUM
Treatment: Ocular Inflammation and Pain after Cataract Surgery[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Nuplazid
Pimavanserin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7923564 | September 26, 2025 |
| US7732615 | June 3, 2028 |
| US7601740 | April 29, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653283762094{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Acadia Pharmaceuticals
Ingredients: PIMAVANSERIN TARTRATE
Treatment: Parkinson’s disease psychosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Baxdela
Delafloxacin [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9539250 | October 7, 2025 |
| US8273892 | August 6, 2026 |
| US7728143 | November 20, 2027 |
| US8871938 | September 23, 2029 |
| USRE46617 | December 28, 2029 |
[/mk_table][vc_column_text css=”.vc_custom_1653283888258{margin-bottom: 0px !important;}”]Dosage: Oral, Intravenous
Company: Melinta Therapeutics
Ingredients: DELAFLOXACIN MEGLUMINE
Treatment: Acute Bacterial Skin and Skin Structure Infections[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Lenvima
Lenvatinib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7253286 | October 24, 2025 |
| US7612208 | September 19, 2026 |
| US11186547 | August 26, 2035 |
| US10407393 | August 26, 2035 |
| US10259791 | August 26, 2035 |
[/mk_table][vc_column_text css=”.vc_custom_1653284017129{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Eisai Inc
Ingredients: LENVATINIB MESYLATE
Treatment: Thyroid Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Cresemba
Isavuconazole[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6812238 | October 31, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653284122063{margin-bottom: 0px !important;}”]Dosage: Oral, Intravenous
Company: Astellas Pharma
Ingredients: ISAVUCONAZONIUM SULFATE
Treatment: Aspergillosis and Mucormycosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Lybalvi
Olanzapine/samidorphan[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7262298 | November 23, 2025 |
| US9119848 | August 30, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1653284210833{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Alkermes, Inc
Ingredients: OLANZAPINE; SAMIDORPHAN L-MALATE
Treatment: Schizophrenia and Bipolar Disorder[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Opsumit
Macitentan[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7094781 | December 5, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653284294480{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Actelion Pharmaceuticals
Ingredients: MACITENTAN
Treatment: Pulmonary Arterial Hypertension[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Latuda
Lurasidone[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE45573 | December 23, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1653284367674{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Sunovion Pharmaceuticals
Ingredients: LURASIDONE HYDROCHLORIDE
Treatment: Schizophrenia and Bipolar Disorder[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Klisyri
Tirbanibulin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8980890 | December 28, 2025 |
| US8236799 | December 28, 2025 |
| US7300931 | February 6, 2026 |
| US7851470 | February 2, 2029 |
| US10669236 | September 7, 2038 |
[/mk_table][vc_column_text css=”.vc_custom_1653284571395{margin-bottom: 0px !important;}”]Dosage: Topical
Company: Almirall, LLC.
Ingredients: TIRBANIBULIN
Treatment: Actinic Keratosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Signifor
Pasireotide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8299209 | December 27, 2025 |
| US7473761 | December 14, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653284454936{margin-bottom: 0px !important;}”]Dosage: Subcutaneous Injection, Intramuscular Injection
Company: Recordati Rare Diseases Inc.
Ingredients: PASIREOTIDE DIASPARTATE
Treatment: Cushing’s Disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1615816365701{margin-bottom: 0px !important;}”]Conclusion
As a drug patent expires it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.
With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it? Well, let’s start with getting in touch by filling the form below and we’ll get back to you in no time.
Authored by: Divya Goyal, Team Lead, Life Science Team, and Madan Ekhande, Research Analyst, Life Science Team[/vc_column_text][/vc_column][/vc_row]
